Yuhan USA Corporation is a regional subsidiary of Yuhan Corporation, Korea’s largest pharmaceutical company with a 93-year heritage. As an outpost of Yuhan’s globalization strategy, Yuhan USA is seeking new opportunities to expand its business domain through searching for new drug materials and companies that match with Yuhan’s targeted therapeutic areas under its open innovation platform. Yuhan USA currently focuses its efforts on global in-licensing and strategic investment in the areas of targeted therapy, immuno-oncology, NASH, and metabolic disease.